Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

GRAL vs CRL: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CRL Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 6–4 Matrix Metrics)

CRL Overall Winner 6-Pillar Tally: GRAL 1 – 5 CRL Matrix Metrics: GRAL 4 – 6 CRL

As of Nov 16, 2026, Charles River Laboratories International, Inc. (CRL) is the stronger overall head-to-head candidate over GRAIL, Inc. (GRAL) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). GRAL carries a Unified Composite Score of 54.5/100 (HOLD) at $105.60 (1.1x Forward P/E, -332.0% operating margin), whereas CRL carries 48.0/100 (HOLD) at $335.52 (25.9x Forward P/E, 14.3% operating margin).

  • Composite vs. Pillar Nuance: While GRAL currently prints a higher short-term Unified Composite Score (54.5/100 HOLD vs. CRL 48.0/100 HOLD), CRL captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (14.3% vs. -332.0% operating margin) and revenue trajectory (-2.2% vs. +3.7% YoY).
  • Technical & Structure Timing Caution: GRAL is currently in a Breakdown options structure phase (RSI 37.7); meanwhile CRL trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 51.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About GRAL vs CRL
GRAL NASDAQ
GRAIL, Inc. Common Stock
Services-Medical Laboratories
$105.60
-8.88% 1D
Market Cap $5.2B
TTM Revenue $167M
Forward P/E 1.1x
Beta / 30D Vol 3.09β · 99% Vol
Unified Composite Score
54.5 / 100 HOLD
Tech 35.0 Fund 49.0 Flow 57.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 38
RSI-14: 37.7 · SMA20: $132.32 · SMA50: $121.37
CRL NYSE Head-to-Head Winner
Charles River Laboratories International, Inc.
Services-Commercial Physical & Biological Research
$335.52
-0.72% 1D
Market Cap $16.2B
TTM Revenue $3.98B
Forward P/E 25.9x
Beta / 30D Vol 1.09β · 68% Vol
Unified Composite Score
48.0 / 100 HOLD
Tech 39.0 Fund 39.0 Flow 50.0 Mom 25.9
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (7.8% over 20 days), RSI 51
RSI-14: 51.4 · SMA20: $344.72 · SMA50: $312.00

6-Pillar Scorecard Institutional Category Breakdown (GRAL 1 – 5 CRL)

Columns: Metric · GRAL · CRL
1. Valuation Multiples GRAL
Forward P/E 1.1x 25.9x
Trailing P/E 1.1x N/M
PEG Ratio N/M 0.13x
EV / Revenue 31.6x 4.1x
2. Growth & Scale CRL
Revenue Growth (YoY) +3.7% -2.2%
Earnings Growth (YoY) +0.0% +523.6%
TTM Revenue (USD) $167M $3.98B
Market Cap $5.2B $16.2B
3. Profitability & Quality CRL
Gross Margin 46.7% 35.1%
Operating Margin -332.0% 14.3%
Net Profit Margin -243.8% 1.0%
Return on Equity (ROE) -17.3% 1.3%
4. Balance Sheet & Cash Flow CRL
Cash Generation (TTM) -$312M $909M EBITDA
Cash Flow Margin N/A 22.9% EBITDA Mgn
Net Cash / Leverage $57M Net Debt (0.03x D/E) $67.40 Book/Sh · 1.3% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CRL
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 93.0% (53rd %ile) 38.8% (11th %ile)
Put/Call OI Skew 0.81x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Neutral NEUTRAL · Markup
6. R&D & Supply-Chain Moat CRL
OpEx & R&D Intensity N/A 20.8% of Rev ($827M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Diagnostics & Research Operator Diagnostics & Research Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: GRAL (4) vs CRL (6)
Institutional Metric GRAL CRL Criterion Row Edge
Market Capitalization
Scale
$5.2B $16.2B Larger Scale CRL
Trailing P/E Ratio
Valuation
1.1x N/M Lower Multiple GRAL
Forward P/E Ratio
Valuation
1.1x 25.9x Lower Multiple GRAL
Revenue Growth (YoY)
Growth
+3.7% -2.2% Higher Growth GRAL
Operating Margin (TTM)
Profitability
-332.0% 14.3% Higher Margin CRL
Net Profit Margin
Profitability
-243.8% 1.0% Higher Margin CRL
Return on Equity (ROE)
Capital Efficiency
-17.3% 1.3% Higher ROE CRL
52-Week Range Position
Momentum
51% ($42–$166) 81% ($146–$380) Stronger Trend CRL
Beta / 30D Volatility
Risk Regime
3.09β · 99% Vol 1.09β · 68% Vol Lower Realized Risk CRL
Unified Institutional Score
Composite Signal
54.5 / 100 (HOLD) 48.0 / 100 (HOLD) Higher Composite GRAL
Trailing 12M Revenue (USD)
Operating Scale
$167M $3.98B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
46.7% 35.1% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 31.6x EV/Rev 0.13x PEG · 4.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$312M ($57M Net Debt (0.03x D/E)) $909M EBITDA ($67.40 Book/Sh · 1.3% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CRL +22.14 pp
GRAL: -10.36% · CRL: +11.78%
3M Horizon GRAL +33.91 pp
GRAL: +50.96% · CRL: +17.05%
6M Horizon CRL +45.39 pp
GRAL: +77.03% · CRL: +122.42%
1Y Horizon CRL +71.37 pp
GRAL: +26.92% · CRL: +98.29%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on GRAL vs CRL. Trailing 12-month operating profitability (GRAL -332.0% vs CRL 14.3%) and valuation multiples (GRAL 1.1x vs CRL 25.9x Forward P/E) are benchmarked directly in Pillar 4 below.

GRAL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$167M
Gross Margin46.7%
Op. Margin-332.0%
ROE / Fwd P/E-17.3% · 1.1x
CRL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$3.98B
Gross Margin35.1%
Op. Margin14.3%
ROE / Fwd P/E1.3% · 25.9x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
GRAL BREAKDOWN
12d in phase · OBV DISTRIBUTION
Current IV 93.0%
IV Percentile 53rd %ile
Put/Call OI Skew 0.81x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact GRAL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CRL UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 38.8%
IV Percentile 11th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CRL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
GRAL Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $5.2B market capitalization and -332.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CRL Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $16.2B market capitalization and 14.3% operating margin.
OpEx & R&D Reinvestment 20.8% of Rev ($827M)
90D Engineering Disclosures 0 Published

Investor FAQ GRAL vs CRL Key Questions & Quantitative Answers

As of Nov 16, 2026, Charles River Laboratories International, Inc. (CRL) is the stronger overall head-to-head candidate over GRAIL, Inc. (GRAL) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). GRAL carries a Unified Composite Score of 54.5/100 (HOLD) at $105.60 (1.1x Forward P/E, -332.0% operating margin), whereas CRL carries 48.0/100 (HOLD) at $335.52 (25.9x Forward P/E, 14.3% operating margin). Composite vs. Pillar Nuance: While GRAL currently prints a higher short-term Unified Composite Score (54.5/100 HOLD vs. CRL 48.0/100 HOLD), CRL captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (14.3% vs. -332.0% operating margin) and revenue trajectory (-2.2% vs. +3.7% YoY). Technical & Structure Timing Caution: GRAL is currently in a Breakdown options structure phase (RSI 37.7); meanwhile CRL trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 51.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CRL leads the Growth & Scale pillar: GRAL posts +3.7% YoY revenue growth and +0.0% YoY earnings growth on $167M TTM revenue (46.7% gross margin, -332.0% operating margin), compared with CRL at -2.2% YoY revenue growth and +523.6% YoY earnings growth on $3.98B TTM revenue (35.1% gross margin, 14.3% operating margin). On trailing 12-month operating scale, GRAL generates $167M in USD-normalized revenue versus $3.98B for CRL. In operating R&D and SG&A reinvestment, GRAL deploys N/A (0 90-day corporate R&D disclosures) versus 20.8% of Rev ($827M) (0 disclosures) for CRL.

GRAL screens cheaper on headline valuation multiples. GRAL trades at 1.1x Forward P/E, 1.1x Trailing P/E, N/M PEG, and 31.6x EV/Revenue (unreported FCF margin), whereas CRL trades at 25.9x Forward P/E, N/M Trailing P/E, 0.13x PEG, and 4.1x EV/Revenue (22.9% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against GRAL (-17.3% ROE) versus CRL (1.3% ROE) capital efficiency.

In options market volatility and institutional positioning, GRAL carries 93.0% implied volatility (53rd %ile, Balanced (25th–60th %ile)), a 0.81x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (3.09β · 99% Vol realized risk). By comparison, CRL carries 38.8% implied volatility (11th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.09β · 68% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.